Renal Outcomes in the early use of vasopressin in the treatment of septic shock
Key facts
- Who runs it
- Azienda Unita Sanitaria Locale Di Bologna
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 242 people, planned
- Started
- 22 May 2024
- Planned end
- 2 Mar 2026
- Type of study
- Interventional
- Record updated
- 20 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Patients suffering from septic shock hospitalized in an intensive setting within 24 hours of clinical diagnosis
- Capable of expressing informed consent to treatment
- Aged over 18 years and under 80 years of age
- Male and female
- Norepinephrine dosage equal to or greater than 0.25 mcg/kg/min according to the patient's ideal weight (IBW)
Who cannot take part
- Patients undergoing kidney transplant
- Patients with recent acute coronary syndrome (within the previous 7 days)
- Patients with allergy/intolerance to the drugs used in the study
- Patients with a history of end-stage renal failure or already undergoing dialysis treatment (CKD stages 4 and 5, with glomerular filtration < 30 ml/min)
- Patients under 18 years of age or over 80 years of age
- Patients in the absence of consent to participate in the study and to the processing of personal and particular data
- Pregnant patients
- Patients who need to start renal replacement treatment within 24 hours of admission to the ICU for dialysis emergencies that cannot be deferred
- Norepinephrine dosage equal to or greater than 0.5 mcg/kg/min according to the patient's ideal weight (IBW) at enrollment time
- Single kidney patients
- Patients with bilateral renal hypoplasia
- Patients undergoing haemoperfusion with an adsorbent cartridge for bacterial endotoxin
- Patients who died within the first 24 hours of admission to the ICU
- Patients requiring a norepinephrine dosage lower than 0.25 mcg/kg/min in the first 24 hours of hospitalization in the ICU
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Septic shock
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of the study is to verify whether the earlier association of vasopressin and norepinephrine determines variations in terms of the use of renal function replacement techniques in the first 7 days of hospitalization in the Intensive Care Unit (ICU), compared to patients in whom the vasopressin is added only when norepinephrine reaches a higher dosage.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from 2023-509071-16-00, who can take part
- Record updated
- 20 April 2026